Safety profile of ORZEYFUL across pivotal studies

Adverse reactions reported in ≥2% of patients treated with ORZEYFUL and greater than placebo in two phase 3 NT1 studies1

Adverse Reaction

Placebo
(n=76)
%
ORZEYFUL 1 mg
twice daily
(n=60)
%
ORZEYFUL 2 mg*
twice daily
(n=136)
%

Insomnia†

15560

Urinary frequency
(pollakiuria)

55358

Urinary frequency
(micturition urgency)

11516

Salivary hypersecretion

087

Influenza

153

Abdominal pain

031

Oropharyngeal pain

031

Paresthesia

022

Rash

003

Sinusitis

152
Adverse Reaction

Insomnia†

 
Placebo
(n=76) %
1
ORZEYFUL 1 mg twice daily
(n=60) %
55
ORZEYFUL 2 mg* twice daily
(n=136) %
60

Urinary frequency (pollakiuria)

 
Placebo
(n=76) %
5
ORZEYFUL 1 mg twice daily
(n=60) %
53
ORZEYFUL 2 mg* twice daily
(n=136) %
58

Urinary urgency (micturition urgency)

 
Placebo
(n=76) %
1
ORZEYFUL 1 mg twice daily
(n=60) %
15
ORZEYFUL 2 mg* twice daily
(n=136) %
16

Salivary hypersecretion

 
Placebo
(n=76) %
0
ORZEYFUL 1 mg twice daily
(n=60) %
8
ORZEYFUL 2 mg* twice daily
(n=136) %
7

Influenza

 
Placebo
(n=76) %
1
ORZEYFUL 1 mg twice daily
(n=60) %
5
ORZEYFUL 2 mg* twice daily
(n=136) %
3

Abdominal pain

 
Placebo
(n=76) %
0
ORZEYFUL 1 mg twice daily
(n=60) %
3
ORZEYFUL 2 mg* twice daily
(n=136) %
1

Oropharyngeal pain

 
Placebo
(n=76) %
0
ORZEYFUL 1 mg twice daily
(n=60) %
3
ORZEYFUL 2 mg* twice daily
(n=136) %
1

Paresthesia

 
Placebo
(n=76) %
0
ORZEYFUL 1 mg twice daily
(n=60) %
2
ORZEYFUL 2 mg* twice daily
(n=136) %
2

Rash

 
Placebo
(n=76) %
0
ORZEYFUL 1 mg twice daily
(n=60) %
0
ORZEYFUL 2 mg* twice daily
(n=136) %
3

Sinusitis

 
Placebo
(n=76) %
1
ORZEYFUL 1 mg twice daily
(n=60) %
5
ORZEYFUL 2 mg* twice daily
(n=136) %
2
*The 2 ORZEYFUL doses were taken at least 3 hours apart with the second dose taken no later than 1 PM.1
†Includes insomnia, middle insomnia, and initial insomnia.1

Insomnia events1

  • Insomnia occurred in 58% of ORZEYFUL-treated patients and severe insomnia occurred in 1.5% of ORZEYFUL-treated patients
    • Approximately 90% started within the first 2 days of therapy initiation, and 4% began between days 2 and 7 of therapy initiation
    • Approximately 63% resolved within 1 week of onset, and approximately 17% were ongoing at study completion
    • None led to study discontinuation or were classified as serious adverse reactions

Urinary events1

  • Urinary adverse reactions occurred in 63% of ORZEYFUL-treated patients and severe urinary adverse reactions occurred in 1% of ORZEYFUL-treated patients
  • Two ORZEYFUL-treated patients discontinued treatment, one due to frequent urination and the other due to urinary incontinence

Safety profile evaluated in

196 patients

across phase 3 trials1

<3% of patients

treated with ORZEYFUL discontinued due to adverse reactions1

A support representative with a briefcase icon

Connect with us

Get resources and information about ORZEYFUL or request to speak with a Takeda representative

NT1=narcolepsy type 1.

Reference: 1. ORZEYFUL (oveporexton tablets) prescribing information. Takeda Pharmaceuticals.